

## **Conflict of Interest Statement**

**Article title:** Predictive Biomarkers of Sorafenib Efficacy in Advanced Hepatocellular


Carcinoma: Are We Getting There?

**Authors:** Yu-Yun Shao, Chih-Hung Hsu, Ann-Lii Cheng

I certify that the affiliations of all authors listed above with or financial involvement in, within the past 5 years and foreseeable future, any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript are completely disclosed in the manuscript and here.

Yu-Yun Shao has nothing to declare. Chih-Hung Hsu has received fees for serving as a speaker from Bayer, and a consultant for Bayer, Exelixis, and Roche. Ann-Lii Cheng was a consultant of Novartis, Merck Serono, Eisai, Exelixis, and GlaxosmithKline LLC, and received research funding from Sanofi (China) and Chugai Pharma R&D Taiwan Ltd.

Corresponding author (on behalf of all co-authors)

A handwritten signature in black ink, appearing to read 'Chih-Hung Hsu', written in a cursive style.

Chih-Hung Hsu, M.D., Ph.D.,

Department of Oncology, National Taiwan University Hospital

7 Chung-Shan South Road, Taipei 10002, Taiwan

Phone: +886 2 23123456 ext. 67680

Fax: +886 2 23711174

E-mail: [chihhungsu@ntu.edu.tw](mailto:chihhungsu@ntu.edu.tw)